TIDMNFX
RNS Number : 6304J
Nuformix PLC
24 August 2021
Nuformix plc
("Nuformix" or the "Company")
Results of Annual General Meeting
Nuformix plc (LSE: NFX), a pharmaceutical development company
targeting unmet medical needs in fibrosis and oncology via drug
repurposing, announces that all resolutions proposed at its Annual
General Meeting held today were duly passed. The results are set
out below:
The Q&A for AGM will be available on the website later this
week.
Resolution Ordinary/ For Against Total votes
Special cast
No. of % No. of %
votes votes
----------------------------------- ---------- ----------- ------- ---------- ------ ------------
To receive the annual
report and accounts
for the year ended
1 31 March 2021 Ordinary 41,314,178 99.97% 10,888 0.03% 41,325,066
----------------------------------- ---------- ----------- ------- ---------- ------ ------------
To approve the Remuneration
2 Policy Ordinary 40,759,964 98.58% 586,866 1.42% 41,346,830
----------------------------------- ---------- ----------- ------- ---------- ------ ------------
To re-appoint Annual
3 Report on Remuneration Ordinary 40,862,374 98.88% 462,692 1.12% 41,325,066
----------------------------------- ---------- ----------- ------- ---------- ------ ------------
To re-appoint Alastair
4 Riddell as a director Ordinary 40,811,768 98.71% 531,941 1.29% 41,343,709
----------------------------------- ---------- ----------- ------- ---------- ------ ------------
To re-appoint Julian
5 Gilbert as a director Ordinary 41,211,768 99.68% 131,941 0.32% 41,343,709
----------------------------------- ---------- ----------- ------- ---------- ------ ------------
To re-appoint s
Madeleine Kennedy
6 as a director Ordinary 41,162,427 99.56% 181,282 0.44% 41,343,709
----------------------------------- ---------- ----------- ------- ---------- ------ ------------
To re-appoint Anne
7 Brindley as a director Ordinary 40,811,768 98.71% 531,941 1.29% 41,343,709
----------------------------------- ---------- ----------- ------- ---------- ------ ------------
To re-appoint haysmacintyre
8 as auditor Ordinary 41,211,768 99.97% 10,888 0.03% 41,222,656
----------------------------------- ---------- ----------- ------- ---------- ------ ------------
To authorise the
Directors to determine
9 the auditor's fees. Ordinary 40,953,492 99.05% 393,338 0.95% 41,346,830
----------------------------------- ---------- ----------- ------- ---------- ------ ------------
To authorise the
Directors to allot
10 shares. Ordinary 40,362,427 97.50% 1,036,813 2.50% 41,399,240
----------------------------------- ---------- ----------- ------- ---------- ------ ------------
To authorise the
Directors to disapply
11 pre-emption rights. Special 39,584,831 95.50% 1,864,409 4.50% 41,449,240
----------------------------------- ---------- ----------- ------- ---------- ------ ------------
To authorise the
Company to purchase
12 its own shares. Special 41,286,601 99.61% 162,639 0.39% 41,449,240
----------------------------------- ---------- ----------- ------- ---------- ------ ------------
To authorise calling
of a general meeting
on 14 clear days'
13 notice. Special 41,438,352 99.97% 10,888 0.03% 41,449,240
----------------------------------- ---------- ----------- ------- ---------- ------ ------------
(1) A vote withheld is not a vote under English law and is
therefore not included in the calculation of votes for and against
a resolution.
In accordance with Listing Rule 9.6.2, a copy of all resolutions
passed as special business will
shortly be available for inspection at the National Storage
Mechanism document viewing facility
at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
Enquiries:
Nuformix plc via Walbrook
Dr Alastair Riddell, Non-Executive
Chairman
Dr Anne Brindley, CEO
Allenby Capital Limited +44 (0) 20 3328 5656
Nick Athanas / George Payne (Corporate
Finance)
Stefano Aquilino / Matt Butlin (Sales
and Corporate Broking)
Walbrook PR nuformix@walbrookpr.com or +44 (0)20
7933 87 80
Anna Dunphy / Phillip Marriage Tel: +44 (0)7876 741 001 / +44
/ Kiki Zaccagnini (0)7980 541 893
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing. The
Company aims to use its expertise in discovering, developing and
patenting novel drug forms, with improved physical properties, to
develop new products in new indications that are, importantly,
differentiated from the original (by way of dosage, delivery route
or presentation), thus creating new and attractive commercial
opportunities. Nuformix has an early-stage pipeline of preclinical
and Phase 1-ready assets with potential for significant value and
early licensing opportunities.
For more information, please visit www.nuformix.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGBZLFLFVLEBBE
(END) Dow Jones Newswires
August 24, 2021 06:57 ET (10:57 GMT)
Nuformix (LSE:NFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nuformix (LSE:NFX)
Historical Stock Chart
From Jul 2023 to Jul 2024
